Characterising the behaviour of poorly water soluble drugs in the intestine: Application of biorelevant media for solubility, dissolution and transport studies

Journal of Pharmacy and Pharmacology

Volumn 62, Issue 11, 2010, Pages 1656-1668

  Kleberg, Karen ^a   Jacobsen, Jette ^a   Müllertz, Anette ^b  

^a Department of Pharmaceutics and Analytical Chemistry ^*  (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

bile salt; biorelevant media; dissolution; intestinal permeability; poorly water soluble drugs

Indexed keywords

BILE SALT; CELECOXIB; CINNARIZINE; CYCLOSPORIN A; DANAZOL; DIAZEPAM; DICLOFENAC; DIPYRIDAMOLE; FATTY ACID; FELODIPINE; FENOFIBRATE; GEMFIBROZIL; GLIBENCLAMIDE; GRISEOFULVIN; INDOMETACIN; KETOCONAZOLE; MONOACYLGLYCEROL; MONTELUKAST; NIFEDIPINE; NNC 25 0926; OCTANOL; PHOSPHOLIPID; SEOCALCITOL; UNCLASSIFIED DRUG;

DRUG ABSORPTION; DRUG PENETRATION; DRUG SOLUBILITY; DRUG TRANSPORT; HYDROLYSIS; IN VIVO STUDY; INTESTINE; INTESTINE FLUID; NONHUMAN; PARTICLE SIZE; PARTITION COEFFICIENT; PH; PREDICTION; REVIEW; TRANSMISSION ELECTRON MICROSCOPY;

BILE ACIDS AND SALTS; BIOLOGICAL TRANSPORT; CHEMISTRY, PHARMACEUTICAL; HUMANS; INTESTINAL ABSORPTION; INTESTINE, SMALL; MODELS, BIOLOGICAL; PERMEABILITY; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS; SOLUBILITY; SURFACE-ACTIVE AGENTS;

EID: 78649653098     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01023.x     Document Type: Review

References (64)

1. Lennernas H, Abrahamsson B,. The use of biopharmaceutic classification of drugs in drug discovery and development: current status and future extension. J Pharm Pharmacol 2005; 57: 273-285.
2. Galia E, et al. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm Res 1998; 15: 698-705.
3. Porter CJ, et al. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov 2007; 6: 231-248.
4. De Smidt PC, et al. Intestinal absorption of penclomedine from lipid vehicles in the conscious rat: contribution of emulsification versus digestibility. Int J Pharm 2004; 270: 109-118.
5. Armand M, et al. Physicochemical characteristics of emulsions during fat digestion in human stomach and duodenum. Am J Physiol 1996; 271: G172-G183.
6. Brouwers J, et al. Intraluminal drug and formulation behavior and integration in in vitro permeability estimation: a case study with amprenavir. J Pharm Sci 2006; 95: 372-383.
7. Clarysse S, et al. Postprandial evolution in composition and characteristics of human duodenal fluids in different nutritional states. J Pharm Sci 2009; 98: 1177-1192.
8. Hernell O, et al. Physical-chemical behavior of dietary and biliary lipids during intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during duodenal fat digestion in healthy adult human beings. Biochemistry 1990; 29: 2041-2056. (Pubitemid 20085429)
9. Kalantzi L, et al. Canine intestinal contents vs. simulated media for the assessment of solubility of two weak bases in the human small intestinal contents. Pharm Res 2006; 23: 1373-1381.
10. Kossena GA, et al. Low dose lipid formulations: effects on gastric emptying and biliary secretion. Pharm Res 2007; 24: 2084-2096.
11. Pedersen BL, et al. A comparison of the solubility of danazol in human and simulated gastrointestinal fluids. Pharm Res 2000; 17: 891-894.
12. Perez de la Cruz Moreno, et al. Characterization of fasted-state human intestinal fluids collected from duodenum and jejunum. J Pharm Pharmacol 2006; 58: 1079-1089.
13. Persson EM, et al. The effects of food on the dissolution of poorly soluble drugs in human and in model small intestinal fluids. Pharm Res 2005; 22: 2141-2151.
14. Persson EM, et al. A clinical single-pass perfusion investigation of the dynamic in vivo secretory response to a dietary meal in human proximal small intestine. Pharm Res 2006; 23: 742-751.
15. Mansbach CM, et al. Isolation and properties of the mixed lipid micelles present in intestinal content during fat digestion in man. J Clin Invest 1975; 56: 781-791.
16. Rautureau M, et al. [Bile salts and lipids in aqueous intraluminal phase during the digestion of a standard meal in normal man (author's transl)]. Gastroenterol Clin Biol 1981; 5: 417-425.
17. Tangerman A, et al. Analysis of conjugated and unconjugated bile acids in serum and jejunal fluid of normal subjects. Clin Chim Acta 1986; 159: 123-132.
18. Carey MC, Small DM,. The characteristics of mixed micellar solutions with particular reference to bile. Am J Med 1970; 49: 590-608.
19. Fatouros DG, et al. Colloidal structures in media simulating intestinal fed state conditions with and without lipolysis products. Pharm Res 2009; 26: 361-374.
20. Claessens MMAE, et al. Charged lipid vesicles: effects of salts on bending rigidity, stability, and size. Biophys J 2004; 87: 3882-3893.
21. Pabst G, et al. On the propensity of phosphatidylglycerols to form interdigitated phases. Biophys J 2007; 93: 513-525.
22. Schiller C, et al. Intestinal fluid volumes and transit of dosage forms as assessed by magnetic resonance imaging. Aliment Pharmacol Ther 2005; 22: 971-979.
23. Meyer JH, et al. Effects of viscosity and fluid outflow on postcibal gastric emptying of solids. Am J Physiol 1986; 250: G161-G164.
24. Horter D, Dressman JB,. Influence of physicochemical properties on dissolution of drugs in the gastrointestinal tract. Adv Drug Deliv Rev 2001; 46: 75-87. (Pubitemid 33653415)
25. Parojcic J, et al. Tablet disintegration and drug dissolution in viscous media: paracetamol IR tablets. Int J Pharm 2008; 355: 93-99.
26. Reppas C, et al. Effect of elevated viscosity in the upper gastrointestinal tract on drug absorption in dogs. Eur J Pharm Sci 1998; 6: 131-139.
27. Alvaro D, et al. Biliary secretion of phosphatidylcholine and its molecular species in cholecystectomized T-tube patients: effects of bile acid hydrophilicity. Biochem Med Metab Biol 1986; 36: 125-135.
28. Hofmann AF,. The enterohepatic circulation of bile acids in man. Adv Intern Med 1976; 21: 501-534.
29. Christensen JO, et al. Solubilisation of poorly water-soluble drugs during in vitro lipolysis of medium- and long-chain triacylglycerols. Eur J Pharm Sci 2004; 23: 287-296.
30. Vertzoni M, et al. Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects. J Pharm Pharmacol 2004; 56: 453-462.
31. Zangenberg NH, et al. A dynamic in vitro lipolysis model. I. Controlling the rate of lipolysis by continuous addition of calcium. Eur J Pharm Sci 2001; 14: 115-122.
32. Wang G, Wang T,. Oxidative stability of egg and soy lecithin as affected by transition metal ions and pH in emulsion. J Agric Food Chem 2008; 56: 11424-11431.
33. Jantratid E, et al. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm Res 2008; 25: 1663-1676.
34. Nielsen FS, et al. Characterization of prototype self- nanoemulsifying formulations of lipophilic compounds. J Pharm Sci 2007; 96: 876-892.
35. Sunesen VH, et al. In vivo in vitro correlations for a poorly soluble drug, danazol, using the flow-through dissolution method with biorelevant dissolution media. Eur J Pharm Sci 2005; 24: 305-313.
36. Boni JE, et al. Instant FaSSIF and FeSSIF-biorelevance meets practicality. Dissolution Technol 2009; 16: 41-45.
37. Kleberg K, et al. Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity. J Pharm Sci 2010 (in press).
38. Fatouros DG, et al. Physicochemical characterization of simulated intestinal fed-state fluids containing lyso-phospati-dylcholine and cholesterol. Dissolution Technol 2009; 16: 47-50.
39. Clarysse S, et al. Postprandial changes in solubilizing capacity of human intestinal fluids for BCS class II drugs. Pharm Res 2009; 26: 1456-1466.
40. Ilardia-Arana D, et al. Biorelevant dissolution media: aggregation of amphiphiles and solubility of estradiol. J Pharm Sci 2006; 95: 248-255.
41. Shono Y, et al. Prediction of food effects on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based pharmacokinetic modeling. Eur J Pharm Biopharm 2009; 73: 107-114.
42. Luner PE, et al. The effects of bile salts and lipids on the physicochemical behavior of gemfibrozil. Pharm Res 1994; 11: 1755-1760.
43. Grove M, et al. Bioavailability of seocalcitol I: relating solubility in biorelevant media with oral bioavailability in rats-effect of medium and long chain triglycerides. J Pharm Sci 2005; 94: 1830-1838.
44. Lue BM, et al. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorly-soluble model compound. Eur J Pharm Biopharm 2008; 69: 648-657.
45. Guidance for Industry: Dissolution testing of immediate release solid oral dosage forms. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 1997.
46. Jantratid E, et al. Application of biorelevant dissolution tests to the prediction of in vivo performance of diclofenac sodium from an oral modified-release pellet dosage form. Eur J Pharm Sci 2009; 37: 434-441.
47. Okumu A, et al. Dynamic dissolution testing to establish in vitro/in vivo correlations for montelukast sodium, a poorly soluble drug. Pharm Res 2008; 25: 2778-2785.
48. Wei H, Lobenberg R,. Biorelevant dissolution media as a predictive tool for glyburide a class II drug. Eur J Pharm Sci 2006; 29: 45-52.
49. Hillgren KM, et al. In vitro systems for studying intestinal drug absorption. Med Res Rev 1995; 15: 83-109.
50. Kvietys PR, et al. Jejunal mucosal injury and restitution: role of hydrolytic products of food digestion. Am J Physiol 1991; 261: G384-G391.
51. Ingels F, et al. Simulated intestinal fluid as transport medium in the Caco-2 cell culture model. Int J Pharm 2002; 232: 183-192.
52. Kataoka M, et al. Effect of food intake on the oral absorption of poorly water-soluble drugs: in vitro assessment of drug dissolution and permeation assay system. J Pharm Sci 2006; 95: 2051-2061.
53. Lakeram M, et al. Optimisation of the caco-2 permeability assay using experimental design methodology. Pharm Res 2008; 25: 1544-1551.
54. Lind ML, et al. Development of simulated intestinal fluids containing nutrients as transport media in the Caco-2 cell culture model: assessment of cell viability, monolayer integrity and transport of a poorly aqueous soluble drug and a substrate of efflux mechanisms. Eur J Pharm Sci 2007; 32: 261-270.
55. Meaney CM,., O'Driscoll CM,. A comparison of the permeation enhancement potential of simple bile salt and mixed bile salt: fatty acid micellar systems using the CaCo-2 cell culture model. Int J Pharm 2000; 207: 21-30.
56. Patel N, et al. Use of simulated intestinal fluids with Caco-2 cells and rat ileum. Drug Dev Ind Pharm 2006; 32: 151-161.
57. Udata C, et al. Enhanced transport of a novel anti-HIV agent-cosalane and its congeners across human intestinal epithelial (Caco-2) cell monolayers. Int J Pharm 2003; 250: 157-168.
58. Fossati L, et al. Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs. Int J Pharm 2008; 360: 148-155.
59. Ingels F, et al. Effect of simulated intestinal fluid on drug permeability estimation across Caco-2 monolayers. Int J Pharm 2004; 274: 221-232.
60. Tippin TK, Thakker DR,. Biorelevant refinement of the Caco-2 cell culture model to assess efficacy of paracellular permeability enhancers. J Pharm Sci 2008; 97: 1977-1992.
61. Brouwers J, et al. In vitro behavior of a phosphate ester prodrug of amprenavir in human intestinal fluids and in the Caco-2 system: illustration of intraluminal supersaturation. Int J Pharm 2007; 336: 302-309.
62. Buch P, et al. IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system. J Pharm Sci 2009; 98: 2001-2009.
63. Vertzoni M, et al. Simulation of fasting gastric conditions and its importance for the in vivo dissolution of lipophilic compounds. Eur J Pharm Biopharm 2005; 60: 413-417.
64. Fotaki N, et al. In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis. Eur J Pharm Sci 2005; 24: 115-122.